Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Pill Clear all
Completed Phase 3 Interventional

National Adaptive Trial for PTSD Related Insomnia

NCT03668041
View directory record Official record
Conditions
Insomnia
Interventions
Trazodone, Eszopiclone, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
35
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 30, 2026, 6:33 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

NCT00565227
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Prostate Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions
vorinostat (suberoylanilide hydroxamic acid), docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Not applicable Interventional Results available

Behavioral Economics to Improve Antihypertensive Therapy Adherence

NCT04029883
View directory record Official record
Conditions
Hypertension, Medication Adherence
Interventions
Text Message, Behavior Economic Incentive
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 6:33 PM EDT
Not yet recruiting Phase 4 Interventional

Suvorexant 3 - PE-PC

NCT07686731
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Insomnia, TBI (Traumatic Brain Injury)
Interventions
Suvorexant, Placebo, Prolonged Exposure Therapy for Primary Care (PE-PC)
Drug · Behavioral
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 6:33 PM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6

NCT00000331
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Test Drug, Placebo Drug
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Study of Neural Responses Induced by Antidepressant Effects

NCT02674529
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo, Real-time Neurofeedback fMRI task pre- and post-RCT
Drug · Behavioral
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 4 Interventional Results available

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis

NCT02086188
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 30, 2026, 6:33 PM EDT
Terminated Phase 2 Interventional Results available

A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol

NCT01004705
View directory record Official record
Conditions
Elevated LDL Cholesterol
Interventions
Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),, Simvastatin
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 30, 2026, 6:33 PM EDT
Terminated Phase 4 Interventional

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

NCT04938388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
Semaglutide Pill, Fresh organic vegetables
Drug · Dietary Supplement
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 3 Interventional

Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

NCT00277654
View directory record Official record
Conditions
Bipolar Disorder, Anxiety Disorder
Interventions
Risperidone
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Metabolism of 0.35mg Norethindrone vs 5mg Norethindrone Acetate

NCT05294341
View directory record Official record
Conditions
Contraception
Interventions
Norethindrone Acetate 5 MG, Norethindrone 0.35 MG
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 2 Interventional

Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity

NCT04298203
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate, Meal Replacement Therapy, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 30, 2026, 6:33 PM EDT
Terminated Phase 2 Interventional

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

NCT03924154
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
RVT-1201, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 30, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional

Pimavanserin for Insomnia in Veterans With PTSD

NCT05441280
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Insomnia
Interventions
pimavanserin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 30, 2026, 6:33 PM EDT
Terminated Phase 2 Interventional Results available

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

NCT01471379
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Spencer Dorn, MD, MPH
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Idiopathic Intracranial Hypertension Treatment Trial

NCT01003639
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Placebo, Formal weight loss counselling program
Drug · Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 30, 2026, 6:33 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age

NCT03905941
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral combined hormonal contraceptives
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of Actonel for the Prevention of Bone Loss

NCT00452439
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Actonel (Risedronate), Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 2 Interventional

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00511953
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended Release tablets, Gabapentin
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Burbank, California • DeLand, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Combined Hormonal Contraceptives on UPA

NCT02577601
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Study to Treat Major Depressive Disorder With a New Medication

NCT03043560
View directory record Official record
Conditions
Depressive Disorder, Anhedonia
Interventions
Ezogabine, Placebos
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 30, 2026, 6:33 PM EDT
Active, not recruiting Phase 3 Interventional

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

NCT00572169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide, Dexamethasone, Adriamycin, Cisplatin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 30, 2026, 6:33 PM EDT
Completed Not applicable Interventional

Habitual Hypertension Medication Adherence in Arizona

NCT05672797
View directory record Official record
Conditions
Medication Adherence, Habits, Hypertension
Interventions
Wellth app, Habit training
Other · Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 30, 2026, 6:33 PM EDT
Withdrawn Not applicable Interventional

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops

NCT01306266
View directory record Official record
Conditions
Chronic Post-traumatic Headache
Interventions
Rizatriptan, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 49 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 30, 2026, 6:33 PM EDT